320 related articles for article (PubMed ID: 24460826)
1. A case of granulomatosis with polyangiitis and pyoderma gangrenosum successfully treated with infliximab and rituximab.
Donmez S; Pamuk ON; Gedik M; A K R; Bulut G
Int J Rheum Dis; 2014 May; 17(4):471-5. PubMed ID: 24460826
[TBL] [Abstract][Full Text] [Related]
2. Rituximab as a new therapeutic option in granulomatosis with polyangiitis: a report of two cases.
Dalkilic E; Alkis N; Kamali S
Mod Rheumatol; 2012 Jun; 22(3):463-6. PubMed ID: 21847703
[TBL] [Abstract][Full Text] [Related]
3. Infliximab or rituximab for refractory Wegener's granulomatosis: long-term follow up. A prospective randomised multicentre study on 17 patients.
de Menthon M; Cohen P; Pagnoux C; Buchler M; Sibilia J; Détrée F; Gayraud M; Khellaf M; Penalba C; Legallicier B; Mouthon L; Guillevin L
Clin Exp Rheumatol; 2011; 29(1 Suppl 64):S63-71. PubMed ID: 21586199
[TBL] [Abstract][Full Text] [Related]
4. A case of refractory pyoderma gangrenosum treated with a combination of Apligraf and systemic immunosuppressive agents.
Duchini G; Itin P; Arnold A
Adv Skin Wound Care; 2011 May; 24(5):217-20. PubMed ID: 21505282
[TBL] [Abstract][Full Text] [Related]
5. Systemic pyoderma gangrenosum responding to infliximab and adalimumab.
Hubbard VG; Friedmann AC; Goldsmith P
Br J Dermatol; 2005 May; 152(5):1059-61. PubMed ID: 15888172
[TBL] [Abstract][Full Text] [Related]
6. Rituximab for refractory granulomatosis with polyangiitis (Wegener's granulomatosis): comparison of efficacy in granulomatous versus vasculitic manifestations.
Holle JU; Dubrau C; Herlyn K; Heller M; Ambrosch P; Noelle B; Reinhold-Keller E; Gross WL
Ann Rheum Dis; 2012 Mar; 71(3):327-33. PubMed ID: 22021864
[TBL] [Abstract][Full Text] [Related]
7. S3. Rituximab for ANCA-associated vasculitides: the French experience.
Charles P; Guillevin L
Presse Med; 2013 Apr; 42(4 Pt 2):534-6. PubMed ID: 23453207
[No Abstract] [Full Text] [Related]
8. Orbital granulomatosis with polyangiitis (Wegener granulomatosis): clinical and pathologic findings.
Muller K; Lin JH
Arch Pathol Lab Med; 2014 Aug; 138(8):1110-4. PubMed ID: 25076302
[TBL] [Abstract][Full Text] [Related]
9. Rituximab for induction and maintenance therapy in granulomatosis with polyangiitis (Wegener's). Results of a single-center cohort study on 66 patients.
Calich AL; Puéchal X; Pugnet G; London J; Terrier B; Charles P; Mouthon L; Guillevin L;
J Autoimmun; 2014 May; 50():135-41. PubMed ID: 24703438
[TBL] [Abstract][Full Text] [Related]
10. Serum immunoglobulin levels and risk factors for hypogammaglobulinaemia during long-term maintenance therapy with rituximab in patients with granulomatosis with polyangiitis.
Besada E; Koldingsnes W; Nossent JC
Rheumatology (Oxford); 2014 Oct; 53(10):1818-24. PubMed ID: 24831059
[TBL] [Abstract][Full Text] [Related]
11. Refractory Wegener's granulomatosis: effect of rituximab on granulomatous bilateral orbital involvement.
Avshovich N; Boulman N; Slobodin G; Zeina AR; Rosner I; Rozenbaum M
Isr Med Assoc J; 2009 Sep; 11(9):566-8. PubMed ID: 19960854
[No Abstract] [Full Text] [Related]
12. Rituximab therapy for Wegener's granulomatosis refractory to conventional treatment.
Sánchez-Escuredo A; Núñez R; Ibernón M; Martínez E; López D; Navarro M; Bonet J; Ara J; Romero R
Nefrologia; 2011; 31(4):502-4. PubMed ID: 21738261
[No Abstract] [Full Text] [Related]
13. Infliximab for treatment of pyoderma gangrenosum associated with inflammatory bowel disease.
Regueiro M; Valentine J; Plevy S; Fleisher MR; Lichtenstein GR
Am J Gastroenterol; 2003 Aug; 98(8):1821-6. PubMed ID: 12907338
[TBL] [Abstract][Full Text] [Related]
14. Idiopathic pyoderma gangrenosum: successful resolution with infliximab therapy and pro-inflammatory cytokines assessment.
Del Giacco SR; Firinu D; Lorrai MM; Serusi L; Meleddu R; Barca MP; Peralta M; Manconi PE
Acta Derm Venereol; 2012 Jul; 92(4):439-40. PubMed ID: 22392509
[No Abstract] [Full Text] [Related]
15. Adjunction of rituximab to steroids and immunosuppressants for refractory/relapsing Wegener's granulomatosis: a study on 8 patients.
Brihaye B; Aouba A; Pagnoux C; Cohen P; Lacassin F; Guillevin L
Clin Exp Rheumatol; 2007; 25(1 Suppl 44):S23-7. PubMed ID: 17428359
[TBL] [Abstract][Full Text] [Related]
16. Pyoderma gangrenosum associated with Wegener's granulomatosis: partial response to mycophenolate mofetil.
Le Hello C; Bonte I; Mora JJ; Verneuil L; Noël LH; Guillevin L
Rheumatology (Oxford); 2002 Feb; 41(2):236-7. PubMed ID: 11886982
[No Abstract] [Full Text] [Related]
17. [Granulomatosis with polyangiitis - clinical picture and review of current treatment options].
Lembicz M; Batura-Gabryel H; Nowicka A
Pneumonol Alergol Pol; 2014; 82(1):61-73. PubMed ID: 24391073
[TBL] [Abstract][Full Text] [Related]
18. Anti-tumor necrosis factor alpha monoclonal antibody (infliximab) for the treatment of Pyoderma gangrenosum associated with Crohn's disease.
Zaccagna A; Bertone A; Puiatti P; Picciotto F; Sprujevnik T; Santucci R; Rossini FP
Eur J Dermatol; 2003; 13(3):258-60. PubMed ID: 12804985
[TBL] [Abstract][Full Text] [Related]
19. [Pyoderma gangrenosum associated with hidradenitis suppurativa: a case report and review of the literature].
García-Rabasco AE; Esteve-Martínez A; Zaragoza-Ninet V; Sánchez-Carazo JL; Alegre-de-Miquel V
Actas Dermosifiliogr; 2010 Oct; 101(8):717-21. PubMed ID: 20965015
[TBL] [Abstract][Full Text] [Related]
20. Rituximab for severe refractory pediatric Wegener granulomatosis.
Patel AM; Lehman TJ
J Clin Rheumatol; 2008 Oct; 14(5):278-80. PubMed ID: 18824926
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
